2025 WMIF | Lung Cancer | Emerging Treatments Maria Svensson, MD, Lund University, discusses the importance of biomarkers in the field of gastric cancers. In a recent study, she We discussed a novel PD-1 and VEGF bispecific antibody, evonucimab, which is being compared to pembrolizumab in patients
Dealmaking by a pair of pharmas has given the biotech industry its best day of transactions in months, tallying nearly $13 billion in Oncology Update by LucidQuest Episode 25
David Pinato, MD, MRes, PhD, Imperial College London, London, UK, discusses the use of combined PD-1/VEGFR blockade for Dr. Lieu Discusses the Rationale for Combined MEK/VEGF/PD-1 Inhibition in CRC
Compass Therapeutics, Inc. (CMPX) Dr Zhang talks to ecancer at ASCO 2024 about the HARMONi-A phase 3 study which looked at ivonescimab combined with
HARMONi-2: Dr. Liu Discusses Implications, Unanswered Questions, and Next Steps Ivonescimab (SMT112)* - Ivonescimab - Summit Therapeutics Inc.
Oncology Update: Breakthrough Trials, Drug Approvals & New Therapies. Get the latest breakthroughs in oncology research! The PD-L1/VEGF-Aโtargeting bispecific antibody has posted positive response rate results in a third indication, bolstering BioNTech's argument Abstract discussion: Subsets of patients with colorectal cancer - Who benefits and who does not?
Oncoinfo โ Istantanee di Oncologia: seguici su We met in Naples - at the Immunotherapy Bridge Congress Can China's Lung Cancer Drug "Ivonescimab" Topple US "Keytruda"? ๐จ๐ณ vs ๐บ๐ธ Lung Cancer Drug๐ (1 Min)
The Role of Biomarkers in Gastric Cancers Ep. 300 - Biotech's $13B Deal Day, ASCO's Hot Targets, Drug Pricing Threat Bispecific antibodies in cancer immunotherapy
Put on your headphones and dive into our 10-minute audio briefing on why Bristol Myers Squibb (BMS) and BioNTech teamed up Ivonescimab's $20 BILLION Question: Will the FDA Greenlight Summit's Wonder Drug? Is Summit Therapeutics' ($SMMT)
Combined Targeting Against VEGF and PD-1 in Bladder Cancer 3 Things to Know About Summit Therapeutics' Binary Bet
Susanna Varkey Ulahannan, MD, The University of Oklahoma College of Medicine, Oklahoma City, OK, explains the rationale Guru P. Sonpavde, MD, discusses the utility of combining anti-VEGF and antiโPD-1 agents in metastatic urothelial carcinoma. Akeso, Summit PD-1 bispecific crushes Merck's Keytruda in lung
Revolutionizing Oncology: Pfizer's PD-1xVEGF Breakthrough Website: Twitter: Facebook: LinkedIn: Expert Takeaway From WCLC Congress Involving Innovative Bispecific Antibody for NSCLC
Faricimab mechanism of action Discover how BioNTech and Bristol Myers Squibb's PD-1/VEGF bispecific antibody is set to revolutionize cancer treatment. Context and Disclosure Family member, Colin, is undergoing immunotherapy for squamous cell carcinoma. Formerly a scientist at
๐ Meet the next frontier in cancer care: #Ivonescimab (#AK112)! ๐ #dengyuemed Dr. Dan Chen explains how immunotherapy may affect the PD-L1/PD-1 pathway, enabling the body to better detect and fight
Get the key insights from the Phase III HARMONi-2 study, which compares Ivonescimab (AK112) โ a novel PD-1/VEGF bispecific Pfizer (NYSE: PFE) just signed a record-breaking $6.05B licensing deal with 3SBio Inc. (HKG:1530) for a Phase 2 PD-1/VEGF เคเคตเฅเคจเฅเคธเฅเคธเฅเคฎเฅเคฌ: เคเฅเคจ เคฎเฅเค เคฌเคจเคพ เคเฅเคเคธเคฐ เคเคฎเฅเคฎเฅเคจเฅเคฅเฅเคฐเคชเฅ เคเคพ เคจเคฏเคพ เคธเคฟเคคเคพเคฐเคพ
Guest host Dr. Nathan Pennell, of the Cleveland Clinic Taussig Cancer Institute, and Dr. Vamsi Velcheti, of the NYU Langone Ivonescimab has the potential to selectively accumulate in the tumor microenvironment, where PD-1 and VEGF levels are higher compared to healthy tissue. This
HARMONi-02 Comparing Ivonescimab vs. Pembrolizumab in Patients with mNSCLC PD-1/VEGFR blockade for liver cancer Oncology Update: Imfinzi, TEVIMBRA, Taletrectinib & New Trials Stay ahead of the latest developments in oncology and precision
๊ทธ๋ฆฌ๋ ๊ณผํ 102ํ ์๋ฐ ํ ๋ผํจํฑ์ค์ VEGF x PD1 ์ด์คํญ์ฒด ์ด๋ณด๋ค์๋ง์ ๊ณผํ. ๋จ์ํ ํ์ด 4๊ฐ๊ฐ ์๋๋ค WCLC 2025 Highlights: FLAURA2, HARMONi, ALCHEMIST with Dr. Balazs Halmos The three biggest biotech deals from May 1. Regeneron buys 23andMe 2. Pfizer buys a PD1-VEGF bispecific antibody 3. Eli Lilly
Join us in this episode of the Oncology Brothers podcast as we dive into the highlights from the World Conference on Lung Oncology Update by LucidQuest Episode 28
Oncology Update by LucidQuest Episode 16 Time-stamped agenda 00:00:00 Introduction of BioVerse 00:02:51 Self-introduction of speakers 00:06:38 Agenda for today's talk
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd. Save. Future perspectives in lung cancer
Panelists Mark A. Socinski, MD; John V. Heymach, MD, PhD; and Dean F. Bajorin, MD, highlight the potential benefits of Pipeline & Therapeutic Focus 1. CTX-009 (Tovecimig) Mechanism: A bispecific antibody targeting both DLL4 and VEGF-A. Oncology Updates: VORANIGO CHMP Nod, Tagrisso OS Boost, KRAS G12D Fast Track and More From Europe's first IDH-mutant
Top Biotechs at ASCO: Michelle Xia on Building Akeso and Advancing Dual-Target Immunotherapy ๐ฆ ๐ฅ ๐๐๐ข๐ก๐ง๐๐๐'๐ฆ ๐ฃ๐-๐ญ/๐ฉ๐๐๐ ๐๐๐ฆ๐ฃ๐๐๐๐๐๐ ๐๐ก๐ง๐๐๐ข๐๐ฌ: ๐๐๐ ๐-๐๐๐๐ก๐๐๐ฅ ๐๐ก ๐๐๐ก๐๐๐ฅ ๐๐ ๐ ๐จ๐ก๐ข๐ง๐๐๐ฅ๐๐ฃ๐ฌ
BioNTech shares rose after Jefferies upgraded the stock to Buy, driven by the potential of a new cancer drug, developed with "Inside the BMS-BioNTech 'BNT327' Deal: Next-Gen Cancer Immunotherapy in 10 Minutes"
BioNTech's PD-L1/VEGF-A impresses in SCLC as bispecific battle ไพ่พพๆนยฎ PD-1/VEGF bispecific, Ivonescimab injection - Akeso, Inc
Understanding Immunotherapy for NSCLC with PD-1 and PD-L1 Biomarkers This analysis charts the evolution of cancer immunotherapy, framed by two pivotal Nobel Prizes. The 2018 award for CTLA-4 and
Immunotherapy Breakthroughs Explained #NobelImmunotherapy #cancer #Immunotherapy2025#el5 #facts HARMONi-2 Trial: Ivonescimab vs Pembrolizumab in PD-L1+ NSCLC | Phase 3 Results (PL02.04)
Drs. Mario Dicato and Eric Van Cutsem, along with Dr. Josep Tabernero, chaired the ESMO 15th World Congress on ๐๐ ๐๐ข๐ช ๐ฃ๐๐๐ญ๐๐ฅ'๐ฆ $๐ฒ๐ ๐๐๐๐ ๐๐ฆ ๐ ๐ง๐จ๐ฅ๐ก๐๐ก๐ ๐ฃ๐ข๐๐ก๐ง ๐๐ข๐ฅ ๐๐๐๐ก๐
The biggest selling drug in the world might get toppled เคเคตเฅเคจเฅเคธเฅเคธเฅเคฎเฅเคฌ เคเค เคจเคฏเฅ, เคเฅเคจเฅ เคเฅเคเคธเคฐ เคเฅ เคฆเคตเคพเค เคนเฅ เคเฅ เคซเฅเคซเคกเคผเฅ เคเฅ เคเฅเคเคธเคฐ เคเฅ เคเคฒเคพเค
Ivonescimab's $20 BILLION Question: Will the FDA Greenlight Summit's Wonder Drug? Michael Atkins, MD, of Georgetown University, Washington, DC, discusses the issues involved in the combined blockade of Learn more about lung cancer at This animation provides an overview of immunotherapy for
AK112, a novel PD-1/VEGF bispecific antibody, in combination with Donald Harvey, PharmD, BCOP, FCCP, FHOPA, from the Winship Cancer Institute, Atlanta, GA, gives a pharmacist's perspective Bristol Myers Squibb is entering a licensing agreement worth up to $11.1 billion with BioNTech to jointly develop and
Dr. McDermott on VEGF/PD-1 Inhibition in RCC In this episode of Top Biotechs at ASCO, recorded at ASCO 2025, Dr. Michelle Xia, Founder and CEO of Akeso Biopharma,
PD-L1/PD-1 Pathway: A Security Checkpoint Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech
AK112 (Ivonescimab Injection) is an innovative PD-1/VEGF bispecific tumor immunotherapy medication. Oncology Update Episode 5 Merck Enters into Exclusive Global License for LM-299, An
AK112 is the first-in-class humanized IgG1 bispecific antibody targeting programmed death-1 (PD-1) and VEGF. This study aimed to evaluate the PD1 ร VEGF blocking bispecifics for cancer draw big backing Dual Blocking of PD-1 & VEGF1. Increased Avidity in TME1. VEGF-A efficiently *There are no known PD-1-based bispecific antibodies approved by the
Oncology Updates: Keytruda Approval, Nanobody Breakthrough, Radioligand Deal and More From Canada's regulatory Lung cancer is the third most common cancer in the U.S. and the leading cause of cancer death. While much therapeutic
Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, shares her perspectives on key ongoing research topics GlycoMimetics, Inc. (NASDAQ: GLYC) is a company in the final stages of a complete corporate transformation following a pivotal BioNTech & Bristol Myers Ink $11.1B Cancer Drug Pact #BNTX #BNTXStock #BNTXNews #BNTXStockNews
Pfizer moves into the VEGF bispecific fast lane | ApexOnco - Clinical Combined blockade of VEGF and PD-1 signaling in RCC
Design of a fragment crystallizable-engineered tetravalent bispecific There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials. Months after paying 3SBio $1.25bn for a seat at ASCO22: Novel Therapies in Lung Cancer
Updates in immunotherapy for lung cancer at WCLC 2024 Brian Henick, MD, Herbert Irving Comprehensive Cancer Center, New York, NY, comments on recent developments in
Keytruda: Origin of the Cancer Immunotherapy Blockbuster First, the PD-1 component of the bispecific helps anchor the whole antibody to the surface of the tumor, whereas a separate VEGF drug would BioVerse Episode 21 - AACR2205 Recap & Asian Biotech Innovation Boom
Will Bispecific Antibodies Replace PD-(L)1 Targeted Agents? - ILCN BioNTech Upgraded on New Cancer Drug Potential #BNTX #SMMT #MRK Rationale behind combining a VEGF/Ang2-blocking nanobody and immunotherpay in advanced CRC
lycoMimetics, Inc. (GLYC) Stephen V. Liu, MD, of the Georgetown University School of Medicine and Georgetown's Lombardi Comprehensive Cancer
Pharma and Biotech Daily: Pfizer's $6 Billion Bet, CRISPR Baby Success, and Bio-Rad's Antibody Di bispecific antibody that targets both PD-1 and VEGF. As an example, Riess pointed to work indicating that bispecific cooperative bindings of
Clinical studies have shown that combination therapy of PD-1 and VEGF antibodies significantly improves clinical benefit over PD-1 antibody alone in certain Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy Dr. Sonpavde on Combining VEGF/PD-1 Inhibitors in Metastatic Urothelial Carcinoma
์ด์คํญ์ฒด #ํญ์์ #์ด๋ณด๋ค์๋ง VEGF x PD1 ์ด์คํญ์ฒด ์ค ๊ฐ์ฅ ์์ ์๋ค๊ณ ํ๋จ๋๋ ์ด๋ณด๋ค์๋ง์ ๋จ์ํ ํ์ด 4๊ฐ๊ฐ ์๋๋๋ค! A single bispecific drug makes Summit Therapeutics a highโrisk, highโreward clinical bet. PFS gains exist, but no clear overall Robert L. Ferris, MD, PhD, Lineberger distinguished professor, executive director, UNC Lineberger Comprehensive Cancer
Faricimab is a novel, investigational bispecific antibody that targets both angiopoietin-2 (Ang-2) and vascular endothelial growth China's Akeso Biopharma reports its novel PD-1/VEGF bispecific lung cancer drug, Ivonescimab, showed superior
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and Summit and Akeso pioneered the PD1 ร VEGF blocking bispecific approach, reasoning that since immunotherapeutic PD1/PDL1 checkpoint blockers and
A firstโinโclass, dualโaction bispecific antibody targeting both #PDโ1 and #VEGF-A, Ivonescimab integrates immune checkpoint The challenges of using biomarkers for immunotherapy